MRS. FAY Q NG, RPH
Pharmacy at 23 St, New York, NY
License number
New York 032238
Category
Pharmacy
Type
Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist
Address
Address
2
423 E 23Rd St, New York, NY 10010
7326 186Th St, Flushing, NY 11366
7326 186Th St, Flushing, NY 11366
Phone
(211) 686-7500
(212) 686-7500
(212) 686-7500
Personal information
See more information about FAY Q NG at radaris.comName
Address
Phone
78 Groton St, Staten Island, NY 10312
560 Riverside Dr APT 15D, New York, NY 10027
560 Riverside Dr APT 12L, New York, NY 10027
3975 Sedgwick Ave APT 7H, Bronx, NY 10463
375 S End Ave APT 12P, New York, NY 10280
Professional information
Fay Sue Ng, New York NY - Lawyer
Address:
New York City Law Department
100 189Th St RM 6, New York 10007
(212) 356-0843
100 189Th St RM 6, New York 10007
(212) 356-0843
Licenses:
New York - Currently registered 1983
Compounds, Compositions And Methods For Reducing Toxicity And Treating Or Preventing Diseases
US Patent:
2011031, Dec 22, 2011
Filed:
Aug 27, 2009
Appl. No.:
13/061508
Inventors:
Samuel J. Danishefsky - Englewood NJ, US
Ting-Chao Chou - Paramus NJ, US
Xiaoguang Lei - Chao Yang, CN
Heedong Yun - Tenafly NJ, US
Fay Ng - New York NY, US
John Hartung - New York NY, US
Dalibor Sames - New York NY, US
Ting-Chao Chou - Paramus NJ, US
Xiaoguang Lei - Chao Yang, CN
Heedong Yun - Tenafly NJ, US
Fay Ng - New York NY, US
John Hartung - New York NY, US
Dalibor Sames - New York NY, US
Assignee:
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
International Classification:
A61K 31/7048, C07D 317/26, C07D 317/24, C07D 403/04, C07C 43/315, C07C 33/04, C07D 405/06, C07C 33/30, A61K 31/357, A61K 31/4192, A61K 31/075, A61K 31/047, A61P 35/00, A61P 35/02, A61P 25/28, A61P 25/16, A61P 25/18, A61P 25/08, A61P 29/00, A61P 3/00, A61P 39/02, A61K 31/165, A61K 31/661, A61K 31/427, A61K 31/337, A61K 31/343, A61K 31/196, A61K 31/675, C12N 5/071, C07D 317/20
US Classification:
514 27, 549453, 549454, 548255, 568592, 568855, 568873, 514467, 514359, 514718, 514738, 514730, 514629, 514130, 514365, 514449, 514462, 514567, 514110, 435375
Abstract:
The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).
Heteroaryl Derivatives As Superior Ligands For Nociceptin Receptor Orl-1
US Patent:
2003011, Jun 26, 2003
Filed:
Nov 6, 2002
Appl. No.:
10/288976
Inventors:
Deen Tulshian - Lebanon NJ, US
Ginny Ho - Murray Hill NJ, US
Fay Ng - New York NY, US
Ginny Ho - Murray Hill NJ, US
Fay Ng - New York NY, US
Assignee:
Schering Corporation
International Classification:
A61K031/506, A61K031/46, A61K031/522
US Classification:
514/252180, 514/256000, 514/304000, 514/263320, 544/295000, 544/333000, 546/125000
Abstract:
Novel compounds of the formula
wherein R is optionally substituted heteroaryl or
Ris H or C—Calkyl; and Rand Rare —CH, —OCHor halo; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions therefore, and the use of said compounds in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse are disclosed.